Poo transplant: 'Poo pills' and the fight against superbugs
You might think of it as just some stinky brown waste but scientists are finding lots of useful ways to use human poo.The latest is in the fight against superbug infections - infections that don't respond to antibiotics - using pills filled with freeze-dried faeces. The idea is that stool samples packed with good bacteria from healthy people are put into a pill, taken by someone with a superbug infection and the healthy bacteria will help to flush out the superbugs.According to the UK Health Security Agency, antibiotic resistant infections are on the rise but Dr Blair Merrick who tested the pills says: "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."
Why are superbugs a problem?
Humans have been using antibiotics to treat infections for nearly 100 years. But as taking them became more common in recent years, sometimes in situations where they weren't needed, some strains of bacteria have developed a resistance to types of antibiotics. It means they can be difficult to treat and life-threatening. According to the NHS, the biggest worry is that new strains of bacteria will eventually also become resistant to antibiotics.
How does a poo transplant work?
Poo samples from healthy donors are tested to make sure there are no harmful bugs and undigested food is removed before it's freeze dried into a powder. That's then put into a pill which dissolves in the bowel to released the poopy powder. The study, which was carried out at Guy's and St Thomas' hospitals in London, suggests the superbugs are flushed out of the bowel and replaced by healthy gut bacteria. Poo transplants like this aren't a new thing. They've already been successfully used in treating Clostridium difficile (C. diff) which is a type of bacteria that can cause diarrhoea, stomach ache, loss of appetite and it can also make a person feel sick.Studies are also looking at poo transplants as a treatment for liver disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
32 minutes ago
- Telegraph
NHS boss claims Nigerian mother got the ‘black service'
An NHS boss has claimed his Nigerian mother received the 'black service, not an NHS service' after dying from suspected lung cancer. Lord Victor Adebowale, chairman of the NHS Confederation, which represents all health organisations, said the death of his 92-year-old mother was 'undignified'. His mother Grace, who worked as an NHS nurse for 45 years, died in January, possibly from lung cancer, but it was not detected until after she died. Lord Victor said there were 'too many situations where people that look like me and shades of me don't get the service'. 'It was not the dignified death that we would have wanted for her. It wasn't the death she deserved,' he told the NHS ConfedExpo conference in Manchester. 'So it makes me clear about the need to address the inequity. I think she got a black service, not an NHS service.' Mrs Adebowale emigrated from Nigeria to Scotland in the 1950s and worked as a nurse across mental health, maternity and acute care, during her career. Lord Victor, who grew up in Wakefield, said that he did not want to blame anyone for her death as the details were not yet clear, but he said that he wanted to highlight a 'systematic problem'. 'She lived to the age of 92 and you may think, 'well, she had a good old innings', but for a lot of those years she was in some discomfort, and it looks like she died from cancer,' he said. 'It's still the case that if you look like me, you're more likely to discover that you've got cancer in A&E, and that for me is an example of two different services.' 'Black people have worse outcomes' He added: 'I used the phrase 'black service'... you only have to look at the stats – across all the major disease categories that we talk about, black people have a worse experience and worse outcomes – we've known that for years, I'm not saying anything new.' He said his mother was an example of a wider issue and he was 'sick of it not changing like everyone else, and I'm close enough to it to know that it happens'. He said there was nothing in his mother's medical records to suggest she had cancer, and that she had gone to A&E in 'poor condition' at a hospital that 'was really struggling when she went in'. Lord Victor said his sister had to argue for their mother to be given a room but that they had not found the reason for her death yet. 'We haven't got to the bottom of it, and that's why I'm not blaming anybody, and I don't want to, but I can talk about my experience and my observation of what happened to my mum,' he said. 'How does that happen? I know it does happen. People have chronic diseases and people don't know and they die of them – I know it's more likely to happen if you're black, it's also more likely to happen if you're poor.' Of his mother, whose full name was Grace Amoke Owuren Adebowale, and who worked in various nursing sectors including mental health, acute care and maternity, he said: 'If you are a nurse, it is what you are, it's what you're born to do.' He went on: 'It is not acceptable that someone who looks like me, on average waits 20 minutes longer in A&E than white patients.' Kate Seymour, head of external affairs at Macmillan Cancer Support, said the story highlighted 'the heartbreaking reality for some when it comes to accessing cancer care in this country'. 'It is categorically unacceptable that some people with cancer are having worse experiences simply because of who they are or where they live. The Government in England has a unique opportunity in its upcoming cancer plan to revolutionise cancer care,' she said. An NHS spokesperson said: 'Everyone – no matter their background – should receive the best NHS care possible. 'That's why we are working across the NHS to ensure that happens – from improving access to cancer diagnosis and treatment, to expanding health checks for Black and Asian communities and increasing uptake of blood pressure and cholesterol medication in under-served groups. 'But we know there is much more to do, and tackling health inequalities will form an important part of the upcoming 10 Year Health Plan.'
Medical News Today
35 minutes ago
- Medical News Today
Celiac disease: Is an easier way to diagnose it on the horizon?
Could a blood test diagnose celiac disease without the need to trigger symptoms? Image credit: Alvaro Lavin/Stocksy. Celiac disease has to do with an abnormal immune response of the body to gluten. Experts are interested in the best ways to test for celiac disease. A recent study discovered that a blood test called WBAIL-2 could aid in diagnosing celiac disease and even contribute to biopsy-free diagnosis. Celiac disease occurs when someone's immune system responds abnormally to gluten. Efforts to improve celiac disease diagnosis are ongoing. A study recently published in Gastroenterology evaluated the effectiveness of using a blood test that measures the cytokine interleukin-2 to diagnose celiac disease. The study's results indicated that the test to be highly effective for celiac disease diagnosis, even for people following a gluten-free diet. The test could offer another option to help with celiac disease diagnosis — importantly, one that would not require triggering symptoms to confirm the disease. The authors of the current study note that there is often a delay or lack of diagnosis when it comes to celiac disease. Diagnosis usually involves people having to eat gluten and get biopsies of the small intestine. Celiac disease also has to do with the response of a group of immune cells, CD4+ gluten-specific T-cells. For this study, researchers wanted to determine if the use of a blood test that measures interleukin-2 — a protein produced by some T-cells — release could help to accurately diagnose celiac disease. This research involved a total of 181 adult participants between 18 and 75 years old. Of these participants, 88 had celiac disease, and others were controls. Among controls, 32 participants had a non-celiac gluten sensitivity and were on a gluten-free diet. The rest were healthy controls who did not have gluten sensitivity. All participants provided blood samples, and researchers collected data on medications and medical history. A subset of participants, including healthy controls, participants with non-celiac gluten sensitivity, and treated celiac disease, went on a gluten-free diet for four weeks or more and then consumed gluten for 'a single-dose open-label gluten challenge.' Some participants with treated celiac disease also did an oral gluten challenge that lasted 3 days. If participants underwent the oral gluten challenge, they used diaries to keep track of their symptoms. Researchers utilized a blood test called a WBAIL-2 assay, which measures the release of interleukin-2 in vitro after adding gluten peptides. In general, the test was able to effectively confirm celiac disease, with higher concentrations and fold change of interleukin-2 in participants who had celiac disease. However, the results were less sensitive for participants with a certain, less common genotype. Analysis results also found that the WBAIL-2 assay correlated with age and the number of years participants had been following a gluten-free diet. Next, researchers tested participants' serum levels of interleukin-2 after they did an oral gluten challenge. The levels of interleukin-2 were higher for participants with celiac disease following the oral gluten challenge. Researchers also found these levels 'positively correlated with the WBAIL-2 results.' So, if the levels of interleukin-2 were elevated on one test, they were also elevated on the other. They also tested how the WBAIL-2 results related to the presence of gluten-specific T cells, which were higher among participants with celiac disease. They did find that the presence of these cells, as well as activated versions of these cells, correlated with the WBAIL-2 test. The researchers further found that gluten-specific T cells, activated versions of these cells, and WBAIL-2 increased after participants underwent a gluten challenge. However, one participant had lower gluten-specific CD4+ T cells and a lower WBAIL-2 test on day six. Researchers also looked at treated celiac disease participants and how the tests related to their symptoms after gluten exposure. When it came to gluten-specific T-cells, their frequency was higher in participants who experienced vomiting. The measurement of serum interleukin-2 following the gluten tolerance test was also elevated, as was the WBAIL-2 level. The WBAIL-2 level was also increased greatly for one participant who did not experience vomiting but did report severe tiredness. Further analysis also suggested that activated gluten-specific CD4+ T cells are the cells that lead to gluten-induced production of interleukin-2. The results suggest that the WBAIL-2 assay can help with celiac disease diagnosis, even when people are already following a gluten-free diet. There are some limitations to this study. For one thing, it was performed out of one area, most participants were female, and there were strict inclusion criteria, so it has a limited generalizability. It also had small sample sizes for some subgroups, which means more research may be particularly necessary in these subgroups. Since researchers did not test children or people taking immunosuppressants, more research is needed to see how well this testing method would work in these populations. Researchers also acknowledge an untested 'reproducibility across laboratories.' More research is thus needed before the WBAIL-2 assay can really be used in the clinical setting. Further, the authors did not examine the cost-effectiveness of the WBAIL-2 test and how well this would stack up against current ways of diagnosing celiac disease. Then, the test was not as accurate for some participants with a specific genotype, which means it might not work for everyone. However, the number of participants with this genotype was very small in this study, and it is possible that the level of interleukin-2 response of some participants with this genotype was just not able to be detected by the test. Overall, more research is required regarding this subtype of individuals and the use of this test. Ian Storch, DO, an osteopathic physician specializing in gastroenterology and internal medicine, and an American Osteopathic Association member, who was not involved in this study, spoke to Medical News Today about its findings. 'One limitation of this study is the poor performance in the DQ8 genetic arm, which makes up 10% of celiac patients. This will decrease the sensitivity and specificity for the control group or require HLA typing before the assay is run.' Researchers acknowledge that the serum analysis of interleukin-2 following a gluten challenge does not always line up with the results of the WBAIL-2 assay, which could have to do with the assays' differences. Shilpa Mehra Dang, MD, double board-certified in gastroenterology and internal medicine with Medical Offices of Manhattan and contributor to LabFinder, who was similarly not involved in this research, noted that 'we need to look at bigger samples to really see its clinical usefulness.' In addition to larger studies, research can also focus on more details regarding gluten-specific T cells. Celiac disease is a challenging condition to manage, and accurate diagnosis is important. Researchers suggest that examining WBAIL-2 and serum interleukin-2 after gluten consumption could allow people with celiac disease to not have to get biopsies done to confirm celiac diagnosis. The authors of this study also suggest that the WBAIL-2 assay could also become a first test among people following a gluten-free diet and help with symptom severity prediction. Storch said: 'I do not think that based on the data presented, removal of histology to confirm the diagnosis can be suggested.' Jeffrey D. Davis, DO, CMD, an osteopathic physician specializing in Family Medicine and Preventive Health and an American Osteopathic Association board member, who was not involved in the study, noted the following to MNT : 'I see potential for a commercially available rapid, simple, cost-effective laboratory test for physicians to use to assist in the accurate diagnosis of celiac disease. This study shows that especially in adults already on a gluten-free diet using this lab test versus currently available tests would improve our diagnostic capabilities for Celiac Disease. However, it would most likely be just another tool in our tool box to aid in the diagnosis along with other current diagnostic methods.'
Daily Mirror
2 hours ago
- Daily Mirror
NHS GP shares life-saving check 'everyone' should do monthly
Dr Shireen explained how to complete the check that everyone is recommended to complete on a regular basis An NHS doctor has highlighted an easy check "we should all be doing" as it could help diagnose cancer and save lives. GP and medical educator Dr Shireen has reminded her TikTok (@doctorshireen) followers to check their breasts following Jessie J's cancer diagnosis. The 37-year-old singer has revealed she's been diagnosed with "early breast cancer" and plans to undergo surgery. Praising the Price Tag singer, Dr Shireen said: "Jessie J has very bravely shared that she's been diagnosed with early breast cancer. "In her video, she says that she's holding on to the fact that it was diagnosed early, and she's absolutely right in doing so. The earlier we diagnose breast cancer, the better the prognosis, i.e., the better the outcome." "I'm a GP and today I'm going to share with you what we should all be doing to ensure if we were to get a breast cancer, it'd be picked up early, and that is self-checking," Dr Shireen shared. "Don't forget that breast cancer can affect men, too. So we recommend everyone to check their breasts once a month at least. It's really important for us to know what's normal so that the second that things might start becoming abnormal, we can pick it up quickly." In her video, the GP explained how to complete the check in a few steps. "The first thing you need to do is look, and it's not just looking at the breasts, it's also looking all the way up to the collarbone and into the axilla. "You're looking at the skin, you're looking for any tethering, any puckering, even any eczematous changes. Looking at the nipple for any inversion, any sign of any potential discharge, any changes like that," she said. Dr Shireen continued: "Next is feeling. So again, when we are palpating, we need to go all the way up and all the way into the axilla area. "But if we think about the breast as a round ball, you want to cut it into four quadrants, and you want to palpate each quadrant separately. So the way to do it is you push on one side, and then you literally just feel the area, and you're feeling for any lumps, any swellings, anything new that you're unsure about." The doctor urged people to speak to a GP if they have any health concerns. "If you do notice any of these changes, please make an appointment to speak to your GP. We refer patients to the urgent breast clinic all of the time, and more than 90% of the time it's nothing. But it is really important that if it is a breast cancer that is picked up early, because prognosis is so dependent on that," she said. The NHS explains that how serious breast cancer is depends on how big the cancer is, if the cancer has spread, and your general health. Advice on how to check your breasts is available on the NHS website. It says: "Checking your breasts or chest regularly helps you learn what looks and feels normal for you. This makes it easier to notice any changes that could be a sign of a condition such as breast cancer. You should try to check your breasts or chest about once a month."
